Boston Scientific Stock Rockets on Blowout Q3 Results and Major Medical Wins
Boston Scientific’s Q3 report blew past expectations. Marlborough, MA-based Boston Scientific posted reported net income of $755 M and adjusted EPS of $0.75 timesunion.com chartmill.com, topping the $0.71–$0.72 analysts’ forecast. CEO Mike Mahoney called it “another exceptional quarter of strong performance” prnewswire.com, fueled by robust growth across all businesses. Total sales were $5.065 B, up 20.3% from a year ago prnewswire.com. Importantly, organic revenue grew 15.3%, well above the 12–14% guidance range. U.S. revenues surged ~27% in Q3 investing.com, reflecting strong demand for its interventional cardiology and MedSurg devices.